Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5401_Библиотеки_им_академика_М_И_Перельмана.pdf
274 Herbal Pharmacopeia
encapsulation system is required to optimize the potential therapeutic advantages of herbal extracts.
Sensitive chemicals found in plant extracts are well protected by encapsulation against oxidation
and dehydration processes, which cause the degradation of these extracts. This chapter focuses on
nanocarrier systems to improve the stability of extracts.
12.5.1 proteCtion against degradation and oxidation
Nanocarriers prevent oxidation and degradation using different methods like: (1) acting as a physical barrier; (2) inhibiting enzymatic degradation by developing a diffusion barrier; and (3) controlling the release of drug
i. Physical barrier: Nanocarriers encapsulate the herbal extract inside its core and act as a
physical barrier against external factors like light, heat, PH change, oxygen etc., thereby
preventing the degradation of the herbal extract. If we take the example of micelles, they
incorporate the drug inside the hydrophobic core and shield it from environmental factors
while the hydrophilic shell helps in water solubility [76].
ii. Controlled release: Nanocarrier systems are designed to deliver the controlled release
of encapsulated extracts. In this way, the bioactives are slowly released within the target
tissue, where absorption is more efcient. As a result, the extract is exposed to a harsh
stomach environment for a shorter period, which further enhances its stability [76].
iii. Diffusion barrier: The major challenge involved in the administration of drugs orally is
the degradation of the drug by the stomach and intestinal enzymes. To overcome this problem, researchers demonstrate a promising approach using ionic gelation to form peptide
antibiotic- polyphosphate nanoparticles (NPs). In this method, the drug is present in the
core shielded by a shell made of polyphosphate. This shell, comprised of polyphosphate,
functions as a diffusion barrier that hinders enzymatic movement. In addition to slowing
enzyme diffusion, NPs make it more difcult for enzymes to reach and degrade the drugs
encapsulated within them [77].
12.5.2 exaMple of stability iMproveMent in herbal extraCts
12.5.2.1 Example 1: Stability and Bioavailability Enhancement of Hypericum perforatum
using Micelles (Made up of ASC8 Surfactant) and Vehicles
Hypericum perforatum, commonly called St. John’s Wort (SJW), is a medicinal herb employed to
treat depression. Active components of SJW are lipophilic and poorly absorbed in the body. In addition, these active components are susceptible to enzymatic degradation in GIT.
Challenges: The major challenges related to SJW extracts are poor bioavailability and degrada-
tion by stomach acid and digestive enzymes. In addition, it is sensitive to oxidation and light.
Proposed solution: Researchers proposed utilizing micelles and vesicles to overcome these
problems [78].
Process: Micelles and vesicles can stabilize the SJW extract by using two methods:
Physical barrier: This barrier can shield the SJW extract from a harsh GIT environment that
otherwise might lead to degradation. Niosomes and liposomes are common types of vehicles. They have a closed bilayer structure that resembles the plasma membrane. A bilayer
can provide a more robust barrier to prevent the encapsulated extract from degradation.
Controlled release: In the GIT, the carrier system can offer a controlled release of extract. As
a result, the active components can be gradually released, potentially reducing their exposure to degradation factors such as stomach acid and enzymes [78].
Enhanced Bioavailability of Herbal Extracts using Nanocarriers 275
Photostability and antioxidant properties: According to the study, ASC8 can self- assemble
into micelles in water. These micelles might enclose SJW components, protecting them
from exposure to light and oxygen. ASC8 possesses antioxidant properties. Micelles made
of ASC8 can scavenge free radicals and prevent the oxidative degradation of SJW active
components [79].
12.5.2.2 Example 2: Enhancing Curcumin Stability and Bioavailability using SLNs
Curcumin is an active component of turmeric and possesses various benets as have been detailed
earlier.
Challenges: Curcumin has low solubility in water and susceptibility to rapid enzymatic break-
down in the digestive tract. Both of these challenges lead to the poor bioavailability of
curcumin and limit its therapeutic benets.
Possible solutions: Researchers examined the effects of soy lecithin SLNs on curcumin’s oral
bioavailability. SLNs have several advantages, which mean that they can enhance the aqueous solubility of curcumins. They also protect curcumin from degradation.
Results: Studies show that C- SLNs achieved high drug encapsulation efciency (92.33%).
Also, SLNs enhanced the stability of the drug, i.e. after storage at 5°C for a year, the
C- SLNs exhibited only a 9% decrease in encapsulation efciency. This demonstrates that
formulation will be stable for a long time [80].
12.6 TARGETED DELIVERY AND CONTROLLED RELEASE
Targeted drug delivery in nanocarrier systems involves the precise delivery of medications to specic areas, enhancing effectiveness while minimizing side effects. Nanotechnology has revolutionized drug delivery through the use of various nanoparticle carriers such as liposomes, dendrimers,
and polymeric nanoparticles, each with unique properties and applications. These systems are crucial in treating conditions like tumors and colon cancer, where targeted delivery is essential for
efcient therapy. By leveraging nanocarriers, drugs can be delivered directly to tumor cells, improving treatment outcomes while reducing harm to healthy tissues. Furthermore, in prostate cancer,
functionalized nanocarriers are designed to target specic cell membrane proteins, enhancing the
precision and sensitivity of drug delivery.
12.6.1 Key prinCiples
12.6.1.1 Selectivity and Specicity
The foundation of targeted delivery lies in achieving high selectivity and specicity for the target
site. This can be accomplished through either passive targeting or active targeting.
12.6.1.2 Design and Composition of Nanocarriers
The structural and compositional attributes of nanocarriers are crucial in determining their targeting
efciency:
1. Size and Shape: Optimal sizes (typically 10–200 nm) and shapes (spherical, rod- like) are
selected to enhance circulation time and evade immune detection.
2. Surface Properties: Surface modications such as PEGylation (the attachment of poly-
ethylene glycol) can improve the nanocarrier’s stability and circulation time by reducing
protein adsorption and immune recognition [81].
276 Herbal Pharmacopeia
12.6.1.2.1 Integration and Optimization
The successful implementation of targeted delivery systems requires the meticulous optimization
of various parameters, including the density and orientation of targeting ligands, the physicochemical properties of the nanocarrier, and the selection of appropriate stimuli for controlled release.
Continuous research and development in this eld aim to rene these parameters to enhance the
specicity, efcacy, and safety of nanocarrier- based drug delivery systems [82].
12.6.1.2.2 Advantages of Controlled Release Systems
Controlled release systems offer several advantages over conventional drug delivery methods:
1. Prolonged Therapeutic Effect: By maintaining consistent drug levels, these systems ensure
prolonged efcacy.
2. Reduced Dosing Frequency: Sustained release reduces the need for frequent dosing,
improving patient compliance.
3. Minimized Side Effects: Controlled release minimizes peak–trough uctuations, reducing
the risk of side effects associated with high or low drug concentrations [83].
12.6.1.2.3 Applications in Medicine
Controlled release mechanisms are widely used across various medical elds:
1. Cancer Therapy: Controlled release of chemotherapeutics can reduce systemic toxicity
and improve treatment efcacy.
2. Chronic Diseases: Conditions like diabetes and hypertension benet from sustained drug
release, ensuring stable levels of medication in the bloodstream.
3. Pain Management: Long- acting analgesics provide consistent pain relief without frequent
dosing.
12.7 PHARMACOKINETICS AND PHARMACODYNAMICS
The pharmacokinetic and pharmacodynamic factors inuencing the ADME proles of nanocarriers include the nature of the drug delivery carrier chosen, the properties of the nanomedicines,
and individual variations in organ size and body fat index. Physicochemical properties such as
composition, particle size, shape, surface charge, and modications like PEGylation and functionalization play a crucial role in determining the pharmacokinetics and pharmacodynamics of nanocarriers, affecting their therapeutic performance. Additionally, changes in the backbone and sugar
chemistry of antisense oligonucleotides (ASOs), conjugation approaches, and routes of administration signicantly impact their ADME and pharmacokinetic proles, ultimately inuencing
efcacy and safety. The unique dispositional characteristics of nanocarriers, such as solubilizing
platforms, controlled release mechanisms, and equilibrium binding properties, also contribute to
the complexity of their pharmacokinetics, diverging from traditional drug- protein binding paradigms [84].
12.7.1 enhanCing therapeutiC effiCaCy through pharMaCoKinetiC Modulation
Pharmacokinetic modulation using nanocarriers can signicantly enhance the therapeutic efcacy
of drugs by optimizing their absorption, distribution, metabolism, and excretion (ADME) proles.
12.7.1.1 Sustained Release and Targeted Delivery
Nanocarriers can provide sustained release of drugs, maintaining therapeutic concentrations over
an extended period. This can lead to improved efcacy, reduced dosing frequency, and enhanced
Enhanced Bioavailability of Herbal Extracts using Nanocarriers 277
patient compliance. Targeted delivery of nanocarriers to specic sites or cells can further enhance
therapeutic efcacy by increasing local drug concentrations [76].
12.7.1.2 Improved Bioavailability and Reduced Inter- Individual Variability
Nanocarriers can improve the bioavailability of drugs by protecting them from degradation, enhancing solubility, and increasing permeability across biological membranes. This can reduce interindividual variability in pharmacokinetic responses, leading to more consistent and predictable
therapeutic outcomes [85].
12.7.1.3 Enhanced Pharmacodynamic Effects
The altered pharmacokinetic proles of drugs achieved through nanocarrier modulation can lead
to enhanced pharmacodynamic effects, such as improved efcacy, duration of action, and potency.
This can be particularly benecial for drugs with narrow therapeutic indices or those requiring precise dosing [86].
12.7.1.4 Reduced Adverse Effects and Toxicity
By optimizing the pharmacokinetic proles of drugs, nanocarriers can reduce the risk of adverse
effects and toxicity. This can be achieved by minimizing peak plasma concentrations, reducing offtarget effects, and improving the safety prole of the drug [87].
12.7.1.5 Opportunities for Personalized Medicine
Nanocarrier- based pharmacokinetic modulation offers opportunities for personalized medicine by
allowing for tailored design of nanocarriers to individual patient needs. This can involve optimizing nanocarrier properties, such as size, surface charge, and targeting ligands, to achieve improved
therapeutic outcomes in specic patient populations [88].
12.7.2 CliniCal iMpliCations of iMproved pharMaCodynaMiCs
The utilization of herbal extracts as nanocarriers can lead to enhanced pharmacodynamics with
important implications for clinical use. By using this approach, the bioavailability and therapeutic
effectiveness of herbal medicines can be improved, possibly reducing the negative effects linked to
traditional drug delivery techniques.
1. Personalized Medicine: Utilizing herbal extracts can be personalized based on individual
patient requirements, taking into account factors like genetic composition and particular
health issues. This individualized method has the potential to improve patient results and
compliance with treatment plans.
2. Safety and Efcacy: The safety of herbal supplements is commonly assumed, but their
interaction with traditional medications can present dangers. It is essential for healthcare
providers to grasp the pharmacodynamics of these interactions in order to avoid negative
effects and maintain patient safety. Healthcare professionals need thorough training and
awareness of these interactions to manage patients effectively [89].
3. Regulatory Considerations: The herbal supplement industry’s current absence of regula-
tion is a cause for worry regarding the quality and safety of products. It is crucial to implement stricter regulations and standardized testing for herbal products to guarantee their
effectiveness and safety in clinical use [90].
4. Research and Development: Researching the pharmacokinetic and pharmacodynamic
proles of herbal extracts is crucial. The emphasis should be on understanding the mechanisms of action, possible interactions, and creating standardized formulations that can be
safely incorporated into conventional therapies [89].
278 Herbal Pharmacopeia
12.8 CLINICAL APPLICATIONS AND CASE STUDIES
Nanotechnology has revolutionized cancer therapy and the treatment of chronic diseases by enabling
the development of nanocarrier- based herbal drugs. These innovative drug delivery systems enhance
bioavailability, reduce toxicity, and improve therapeutic efcacy. Clinical applications and case
studies have showcased the successful implementation of nanocarrier- based herbal drugs in cancer
therapy, diabetes, and other chronic illnesses. By encapsulating herbal extracts within nanoparticles,
these nanocarriers offer targeted delivery, increased stability, and enhanced pharmacological activity, overcoming the limitations of traditional herbal medicine. The amalgamation of nanotechnology
with herbal remedies presents promising prospects for personalized medicine and tailored therapies,
demonstrating the transformative potential of nanocarrier- based herbal drugs in improving patient
outcomes and advancing the eld of healthcare.
12.8.1 suCCessful iMpleMentations of nanoCarrier- based herbal drugs
12.8.1.1 Curcumin- Loaded Nanoparticles
Application: Curcumin, derived from turmeric, is known for its anti- inammatory and anti-
cancer properties but suffers from poor bioavailability. Researchers developed curcuminloaded solid lipid nanoparticles (SLNs) that signicantly enhanced its solubility and
stability.
Outcome: Clinical studies indicated improved absorption and therapeutic effects in patients
with chronic inammatory conditions, showcasing the potential of SLNs in delivering curcumin effectively [91].
12.8.1.2 Quercetin- Loaded Liposomes
Application: Quercetin has antioxidant and anti- inammatory properties but is poorly soluble
in water. Liposomal formulations of quercetin were developed to improve its bioavailability.
Outcome: In clinical trials, patients receiving quercetin liposomes showed enhanced antioxi-
dant activity and reduced oxidative stress markers compared to those receiving standard
quercetin supplements. This illustrates the effectiveness of liposomes in enhancing the
therapeutic potential of herbal extracts [92].
12.8.1.3 Ginger Extract Nanocarriers
Application: Ginger extract, known for its anti- nausea and anti- inammatory effects, was
encapsulated in polymeric nanoparticles to enhance its delivery.
Outcome: Studies demonstrated that patients receiving ginger extract via nanoparticle formula-
tions experienced signicant reductions in nausea and vomiting, particularly in chemotherapyinduced cases, compared to those taking conventional ginger supplements [93].
12.8.1.4 Green Tea Extract Nanocarriers
Application: Green tea polyphenols, particularly epigallocatechin gallate (EGCG), were
encapsulated in chitosan nanoparticles to enhance their stability and bioavailability.
Outcome: Clinical studies indicated that patients consuming EGCG- loaded nanoparticles
experienced improved metabolic parameters and reduced oxidative stress, demonstrating
the potential of chitosan nanoparticles in delivering herbal extracts effectively [94].
12.8.2 Challenges and liMitations in CliniCal settings
12.8.2.1 Quality Control and Standardization
One of the primary challenges is ensuring the quality and consistency of herbal extracts used in
nanocarrier formulations. The rising demand for phytopharmaceuticals has led to concerns about
Enhanced Bioavailability of Herbal Extracts using Nanocarriers 279
adulteration and misidentication of raw materials, which can compromise the efcacy and safety
of herbal medicines. Regulatory authorities face difculties in nding high- quality phytopharmaceuticals due to interspecies diversity and variations in vernacular nomenclature, leading to potential
health risks for consumers [91, 95].
12.8.2.2 Limited Encapsulation Capacity
Nanocarriers often have limitations in the amount of herbal active compounds they can encapsulate.
This restriction can hinder the formulation of effective therapeutic doses, necessitating larger quantities of herbal extracts to achieve desired treatment durations. The manufacturing of functionalized
nano- medicinal formulations that can effectively deliver these compounds remains a signicant
obstacle to commercialization [91].
12.8.2.3 Pharmacokinetic and Pharmacodynamic Variability
Herbal extracts often exhibit variability in pharmacokinetics and pharmacodynamics due to differences in plant sources, extraction methods, and individual patient responses. This variability can
complicate the prediction of therapeutic outcomes and the establishment of standardized dosing
regimens for nanocarrier formulations [91].
12.8.2.4 Manufacturing Challenges
The production of nanocarrier systems that are both effective and scalable poses signicant technical challenges. The complexity involved in synthesizing and characterizing nanoparticles, along
with ensuring their stability and compatibility with herbal extracts, can hinder the development of
commercially viable [95, 96].
12.9 FUTURE PERSPECTIVES
12.9.1 advanCing nanoCarrier design and engineering
1. Exploring new materials and compositions for nanocarriers to further improve stability,
drug- loading capacity, and targeted delivery.
2. Developing stimuli- responsive nanocarriers that can release the herbal extracts in a controlled manner based on specic environmental cues.
3. Incorporating multiple functionalities within a single nanocarrier to achieve synergistic
effects, such as combining targeting ligands, imaging agents, and drug payloads.
4. Optimizing the manufacturing processes to enhance the scalability and reproducibility of
nanocarrier production.
12.9.2 expanding the diversity of herbal extraCts forMulated with nanoCarriers
1. Investigating the applicability of nanocarrier technology to a broader range of herbal
extracts, including those with poor solubility, stability, or bioavailability.
2. Evaluating the performance of nanocarriers in delivering synergistic combinations of
phytochemicals from herbal extracts.
3. Exploring the potential of nanocarriers to improve the delivery of herbal extracts for
specic therapeutic areas, such as cancer, inammation, or neurological disorders.
12.9.3 advanCing preCliniCal and CliniCal evaluation
1. Conducting comprehensive in vitro and in vivo studies to assess the pharmacokinetics,
pharmacodynamics, and safety proles of nanocarrier- based herbal extract formulations.
2. Designing robust and standardized protocols for the evaluation of nanocarrier- based herbal
extracts to ensure consistent and reliable data across different research groups.
280 Herbal Pharmacopeia
3. Initiating clinical trials to evaluate the efcacy and tolerability of nanocarrier- based herbal
extract formulations in human subjects, with a focus on demonstrating improved therapeutic outcomes compared to conventional herbal preparations.
12.9.4 addressing regulatory and CoMMerCialization Challenges
1. Engaging with regulatory authorities to establish clear guidelines and frameworks for the
development and approval of nanocarrier- based herbal extract products.
2. Addressing scalability and cost- effectiveness challenges to facilitate the translation of
nanocarrier- based herbal extract formulations from the laboratory to the market.
3. Exploring strategies for intellectual property protection and effective commercialization of
nanocarrier- based herbal extract products.
12.9.5 exploring synergies with other eMerging teChnologies
1. Integrating nanocarrier technology with modern advanced techniques, such as AI- driven
drug design, 3D printing, and personalized medicine, to further enhance the effectiveness
of herbal extract delivery.
2. Investigating the potential of combining nanocarrier- based herbal extracts with other therapeutic modalities, such as photodynamic therapy or gene therapy, for improved clinical
outcomes.
3. Exploring the application of advanced analytical techniques, such as multi- omics approaches,
to obtain a better understanding of the mechanisms of action and optimization of nanocarrierbased herbal extract formulations.
12.10 NANOTECHNOLOGY WITH HERBAL MEDICINE:
OPPORTUNITIES AND CHALLENGES
12.10.1 opportunities
Pharmaceutical scientists are increasingly focusing on developing drug delivery systems for herbal
medicines using scientic methods. Cuscuta chinensis, a widely used traditional Chinese medicine,
contains key components like avonoids and lignans that have limited water solubility. This poor
solubility can hinder their absorption when administered orally. To improve this, researchers have
explored the use of nanoparticles [97, 98]. Recent studies have successfully employed the precipitation method to create polylactic acid nanoparticles for lipophilic anti- cancer compounds such as
cucurbitacins and curcuminoids [99]. Additionally, there has been signicant research into solid
lipid nanoparticles (SLNs) aimed at enhancing the targeted delivery and bioavailability of traditional Chinese herbal medicines [100]. Various nanostructured carrier systems, including polymeric
nanoparticles, liposomes, SLNs, polymeric micelles, and nanoemulsions, have also been investigated for their potential to deliver anticancer drugs via oral routes [101].
Some difculties, such as converting the formulation of bioactive compounds into conventional
dosage forms in herbal remedies, are faced due to their poor solubility or stability. These challenges
could be resolved as nanoparticles provide a diverse platform to incorporate these compounds and
enhance their properties, Marking a convergence of traditional wisdom with cutting- edge technology. The therapeutic potential of natural compounds could be enhanced in an efcient, targeted, and
reliable manner by the encapsulating nanoparticles into herbal remedies. As advances in nanotechnology research continues to progress, the interconnection between nanoparticles and herbal medicine holds a great potential for developing innovative, standardized, and effective therapeutic
solutions with diverse applications in healthcare and wellness [102].
Enhanced Bioavailability of Herbal Extracts using Nanocarriers 281
FIGURE 12.8 Challenges faced by herbal nanotechnology- based medicines.
12.10.2 Challenges
Nanopharmaceuticals may offer countless possibilities for drug delivery to diagnose and treat different conditions, but their safety prole should also be considered. The toxic effects of engineered
nano- sized materials could be a result of the change in the physicochemical and structural properties
and decreased size, leading to several material interactions. Since the data on safety and toxicity is
insufcient, scientists must acknowledge that the toxicological evaluation for nanomaterials and
nanomedicines accept that it is still very early in its development [101]. Some of the key challenges
are described in Figure 12.8.
12.11 CONCLUSION
The integration of nanotechnology into herbal medicine represents a signicant step forward in
enhancing the therapeutic effectiveness and bioavailability of herbal extracts. These advancements
address longstanding challenges associated with their stability and absorption. This chapter has
explored how nanotechnology can overcome the challenges faced by traditional herbal extracts,
such as poor solubility, instability, and low bioavailability. Nanocarriers like liposomes and micelles
have shown great potential in improving the delivery and therapeutic efcacy of phytochemicals.
By enhancing absorption, distribution, and controlled release, these nanocarrier systems can signicantly boost the bioavailability of herbal active compounds. As the eld progresses, future advancements in nanocarrier engineering, integration with emerging technologies, and addressing regulatory
hurdles will further unlock the full potential of herbal medicines. The synergistic combination of
traditional herbal knowledge and modern nanotechnology holds promise to revolutionize integrative
healthcare and improve patient outcomes.
REFERENCES
1. Kunle OF, Egharevba HO, Ahmadu PO. Standardization of herbal medicines – A review. International
Journal of Biodiversity and Conservation. 2012;4(3):101–12.
2. Sachan AK, Kumar A. Stability testing of herbal products. Journal of Chemical and Pharmaceutical
Research. 2015;7(12):511–4.
282 Herbal Pharmacopeia
3. Kesarwani K, Gupta R. Bioavailability enhancers of herbal origin: An overview. Asian Pacic Journal of
Tropical Biomedicine. 2013;3(4):253–66.
4. Stielow M, Witczynska A, Kubryn N, Fijałkowski Ł, Nowaczyk J, Nowaczyk A. The bioavailability of
drugs — The current state of knowledge. Molecules. 2023;28(24):8038.
5. Fotherby K. Pharmacokinetics and pharmacodynamics in drug development. Advances in Contraception.
1991;7:107.
6. Dewi MK, Chaerunisaa AY, Muhaimin M, Joni IM. Improved activity of herbal medicines through nano-
technology. Nanomaterials. 2022;12(22):4073.
7. Puri A, Loomis K, Smith B, Lee J- H, Yavlovich A, Heldman E, et al. Lipid- based nanoparticles as phar-
maceutical drug carriers: From concepts to clinic. Critical Reviews in Therapeutic Drug Carrier Systems.
2009;26(6):523–80.
8. Benet LZ, Kroetz D, Sheiner L, Hardman J, Limbird L. Pharmacokinetics: The dynamics of drug absorp-
tion, distribution, metabolism, and elimination. Goodman and Gilman’s the Pharmacological Basis of
Therapeutics. 1996;3:e27.
9. Feghali M, Venkataramanan R, Caritis S, editors. Pharmacokinetics of drugs in pregnancy. Seminars in
perinatology; 2015: Elsevier.
10. Rahman A, Harwansh R, Mirza A, Hussain S, Hussain A. Oral lipid based drug delivery system (LBDDS):
Formulation, characterization and application: A review. Current Drug Delivery. 2011;8(4):330–45.
11. Mukherjee PK, Venkatesh M, Maiti K, Mukherjee K, Saha B. Value added herbal drug delivery
systems- perspectives and developments. Indian Journal of Pharmaceutical Education and Research.
2009;43(4):329–37.
12. Li Y, Zheng J, Xiao H, McClements DJ. Nanoemulsion- based delivery systems for poorly water- soluble
bioactive compounds: Inuence of formulation parameters on polymethoxyavone crystallization. Food
hydrocolloids. 2012;27(2):517–28.
13. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to esti-
mate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery
Reviews. 1997;23(1–3):3–25.
14. Aqil F, Munagala R, Jeyabalan J, Vadhanam MV. Bioavailability of phytochemicals and its enhancement
by drug delivery systems. Cancer Letters. 2013;334(1):133–41.
15. Brown EJ, Khodr H, Hider CR, Rice- Evans CA. Structural dependence of avonoid interactions with
Cu2+ ions: Implications for their antioxidant properties. Biochemical Journal. 1998;330(3):1173–8.
16. Passamonti S, Terdoslavich M, Franca R, Vanzo A, Tramer F, Braidot E, et al. Bioavailability of a-
vonoids: A review of their membrane transport and the function of bilitranslocase in animal and plant
organisms. Current Drug Metabolism. 2009;10(4):369–94.
17. Hollman PC, Bijsman MN, Van Gameren Y, Cnossen EP, De Vries JH, Katan MB. The sugar moiety is
a major determinant of the absorption of dietary avonoid glycosides in man. Free Radical Research.
1999;31(6):569–73.
18. Scalbert A, Williamson G. Dietary intake and bioavailability of polyphenols. The Journal of nutrition.
2000;130(8):2073S–85S.
19. Walle T, Hsieh F, DeLegge MH, Oatis JE, Walle UK. High absorption but very low bioavailability of oral
resveratrol in humans. Drug metabolism and disposition. 2004;32(12):1377–82.
20. Ravichandran R. Nanoparticles in drug delivery: Potential green nanobiomedicine applications.
International Journal of Green Nanotechnology: Biomedicine. 2009;1(2):B108–B30.
21. Mishra B, Patel BB, Tiwari S. Colloidal nanocarriers: A review on formulation technology, types and applica-
tions toward targeted drug delivery. Nanomedicine: Nanotechnology, biology and medicine. 2010;6(1):9–24.
22. Kulkarni SB, Betageri GV, Singh M. Factors affecting microencapsulation of drugs in liposomes. Journal
of Microencapsulation. 1995;12(3):229–46.
23. Sun T, Shrike Zhang Y, Bo P, Hyun DC, Yang M, Xia Y. Engineered Nanoparticles for Drug Delivery in
Cancer Therapy*. Jenny Stanford Publishing; 2021. p. 31–142.
24. Nsairat H, Khater D, Sayed U, Odeh F, Al Bawab A, Alshaer W. Liposomes: Structure, composition,
types, and clinical applications. Heliyon. 2022;8(5):e09394.
25. Maja L, Željko K, Mateja P. Sustainable technologies for liposome preparation. The Journal of
Supercritical Fluids. 2020;165:104984.
26. Emami S, Azadmard- Damirchi S, Peighambardoust SH, Valizadeh H, Hesari J. Liposomes as carrier vehi-
cles for functional compounds in food sector. Journal of Experimental Nanoscience. 2016;11(9):737–59.
Enhanced Bioavailability of Herbal Extracts using Nanocarriers 283
27. Salunkhe VR, Patil PS, Wadkar GH, Bhinge SD. Herbal liposomes: Natural network for targeted drug
delivery system. Journal of Pharmaceutical Research International. 2021;33:31–41.
28. Bibi S, Lattmann E, Mohammed AR, Perrie Y. Trigger release liposome systems: Local and remote con-
trolled delivery? Journal of Microencapsulation. 2012;29(3):262–76.
29. Agrawal M, Ajazuddin TDK, Saraf S, Saraf S, Antimisiaris SG, et al. Recent advancements in liposomes
targeting strategies to cross blood- brain barrier (BBB) for the treatment of Alzheimer's disease. Journal
of Controlled Release. 2017;260:61–77.
30. Calzoni E, Cesaretti A, Polchi A, Di Michele A, Tancini B, Emiliani C. Biocompatible polymer nanopar-
ticles for drug delivery applications in cancer and neurodegenerative disorder therapies. Journal of
Functional Biomaterials. 2019;10(1):4.
31. Lv S, Sylvestre M, Prossnitz AN, Yang LF, Pun SH. Design of polymeric carriers for intracellular peptide
delivery in oncology applications. Chemical Reviews. 2021;121(18):11653–98.
32. Ding S, Anton N, Vandamme TF, Serra CA. Microuidic nanoprecipitation systems for preparing
pure drug or polymeric drug loaded nanoparticles: An overview. Expert Opinion on Drug Delivery.
2016;13(10):1447–60.
33. Kallinteri P, Garnett MC. Polymeric Nanoparticles for Drug Delivery. Nanotechnologies for the Life
Sciences. 2007.
34. Koo H, Huh MS, Sun I- C, Yuk SH, Choi K, Kim K, et al. In vivo targeted delivery of nanoparticles for
theranosis. Accounts of Chemical Research. 2011;44(10):1018–28.
35. Yoo J, Park C, Yi G, Lee D, Koo H. Active targeting strategies using biological ligands for nanoparticle
drug delivery systems. Cancers. 2019;11(5):640.
36. Son G- H, Lee B- J, Cho C- W. Mechanisms of drug release from advanced drug formulations such as
polymeric- based drug- delivery systems and lipid nanoparticles. Journal of Pharmaceutical Investigation.
2017;47(4):287–96.
37. Fundamentals and Applications of Controlled Release Drug Delivery. 2012.
38. Peppas NA, Hilt JZ, Khademhosseini A, Langer R. Hydrogels in biology and medicine: From molecular
principles to bionanotechnology. Advanced Materials. 2006;18(11):1345–60.
39. Devalapally H, Shenoy D, Little S, Langer R, Amiji M. Poly(ethylene oxide)-modied poly(beta- amino
ester) nanoparticles as a pH- sensitive system for tumor- targeted delivery of hydrophobic drugs: Part 3.
Therapeutic efcacy and safety studies in ovarian cancer xenograft model. Cancer Chemotherapy and
Pharmacology. 2007;59(4):477–84.
40. Torchilin VP. Multifunctional, stimuli- sensitive nanoparticulate systems for drug delivery. Nature
Reviews Drug Discovery. 2014;13(11):813–27.
41. Kamaly N, Yameen B, Wu J, Farokhzad OC. Degradable controlled- release polymers and polymeric
nanoparticles: Mechanisms of controlling drug release. Chemical Reviews. 2016;116(4):2602–63.
42. Castro KCD, Costa JM, Campos MGN. Drug- loaded polymeric nanoparticles: A review. International
Journal of Polymeric Materials and Polymeric Biomaterials. 2022;71(1):1–13.
43. Mason TG, Wilking JN, Meleson K, Chang CB, Graves SM. Nanoemulsions: Formation, structure, and
physical properties. Journal of Physics: Condensed Matter. 2007;19(7):079001.
44. Aboofazeli R. Nanometric- scaled emulsions (nanoemulsions). Iranian Journal of Pharmaceutical
Sciences 2010;9(4):325–6.
45. McClements DJ. Nanoemulsions versus microemulsions: Terminology, differences, and similarities. Soft
Matter 2012;8(6):1719–29.
46. Anuchapreeda S, Fukumori Y, Okonogi S, Ichikawa H. Preparation of lipid nanoemulsions incorporating
curcumin for cancer therapy. Journal of Nanotechnology. 2012;2012:1–11.
47. Hwang YY, Ramalingam K, Bienek DR, Lee V, You T, Alvarez R. Antimicrobial activity of nanoemul-
sion in combination with cetylpyridinium chloride in multidrug- resistant acinetobacter baumannii.
Antimicrobial Agents and Chemotherapy. 2013;57(8):3568–75.
48. Pawar VK, Panchal SB, Singh Y, Meher JG, Sharma K, Singh P, et al. Immunotherapeutic vitamin E
nanoemulsion synergies the antiproliferative activity of paclitaxel in breast cancer cells via modulating
Th1 and Th2 immune response. Journal of Controlled Release. 2014;196:295–306.
49. Klang V, Valenta C. Lecithin- based nanoemulsions. Journal of Drug Delivery Science and Technology.
2011;21(1):55–76.
50. Singh Y, Meher JG, Raval K, Khan FA, Chaurasia M, Jain NK, et al. Nanoemulsion: Concepts, develop-
ment and applications in drug delivery. Journal of Controlled Release. 2017;252:28–49.